Category Archives: Tms

Bloomberg

(Bloomberg) -- From his perch high above Midtown Manhattan, just across from Carnegie Hall, Bill Hwang was quietly building one of the worlds greatest fortunes.Even on Wall Street, few ever noticed him -- until suddenly, everyone did.Hwang and his private investment firm, Archegos Capital Management, are now at the center of one of the biggest margin calls of all time -- a multibillion-dollar fiasco involving secretive market bets that were dangerously leveraged and unwound in a blink.Hwangs most recent ascent can be pieced together from stocks dumped by banks in recent days -- ViacomCBS Inc., Discovery Inc. GSX Techedu Inc., Baidu Inc. -- all of which had soared this year, sometimes confounding traders who couldnt fathom why.One part of Hwangs portfolio, which has been traded in blocks since Friday by Goldman Sachs Group Inc., Morgan Stanley and Wells Fargo & Co., was worth almost $40 billion last week. Bankers reckon that Archegoss net capital -- essentially Hwangs wealth -- had reached north of $10 billion. And as disposals keep emerging, estimates of his firms total positions keep climbing: tens of billions, $50 billion, even more than $100 billion.It evaporated in mere days.Ive never seen anything like this -- how quiet it was, how concentrated, and how fast it disappeared, said Mike Novogratz, a career macro investor and former partner at Goldman Sachs whos been trading since 1994. This has to be one of the single greatest losses of personal wealth in history.Late Monday in New York, Archegos broke days of silence on the episode.This is a challenging time for the family office of Archegos Capital Management, our partners and employees, Karen Kessler, a spokesperson for the firm, said in an emailed statement. All plans are being discussed as Mr. Hwang and the team determine the best path forward.The cascade of trading losses has reverberated from New York to Zurich to Tokyo and beyond, and leaves myriad unanswered questions, including the big one: How could someone take such big risks, facilitated by so many banks, under the noses of regulators the world over?One part of the answer is that Hwang set up as a family office with limited oversight and then employed financial derivatives to amass big stakes in companies without ever having to disclose them. Another part is that global banks embraced him as a lucrative customer, despite a record of insider trading and attempted market manipulation that drove him out of the hedge fund business a decade ago.A disciple of hedge-fund legend Julian Robertson, Sung Kook Bill Hwang shuttered Tiger Asia Management and Tiger Asia Partners after settling an SEC civil lawsuit in 2012 accusing them of insider trading and manipulating Chinese banks stocks. Hwang and the firms paid $44 million, and he agreed to be barred from the investment advisory industry.He soon opened Archegos -- Greek for one who leads the way -- and structured it as a family office.Family offices that exclusively manage one fortune are generally exempt from registering as investment advisers with the U.S. Securities and Exchange Commission. So they dont have to disclose their owners, executives or how much they manage -- rules designed to protect outsiders who invest in a fund. That approach makes sense for small family offices, but if they swell to the size of a hedge fund whale they can still pose risks, this time to outsiders in the broader market.This does raise questions about the regulation of family offices once again, said Tyler Gellasch, a former SEC aide who now runs the Healthy Markets trade group. The question is if its just friends and family why do we care? The answer is that they can have significant market impacts, and the SECs regulatory regime even after Dodd-Frank doesnt clearly reflect that.Valuable CustomerArchegos established trading partnerships with firms including Nomura Holdings Inc., Morgan Stanley, Deutsche Bank AG and Credit Suisse Group AG. For a time after the SEC case, Goldman refused to do business with him on compliance grounds, but relented as rivals profited by meeting his needs.The full picture of his holdings is still emerging, and its not clear what positions derailed, or what hedges he had set up.One reason is that Hwang never filed a 13F report of his holdings, which every investment manager holding more than $100 million in U.S. equities must fill out at the end of each quarter. Thats because he appears to have structured his trades using total return swaps, essentially putting the positions on the banks balance sheets. Swaps also enable investors to add a lot of leverage to a portfolio.Morgan Stanley and Goldman Sachs, for instance, are listed as the largest holders of GSX Techedu, a Chinese online tutoring company thats been repeatedly targeted by short sellers. Banks may own shares for a variety of reasons that include hedging swap exposures from trades with their customers.Unhappy InvestorsGoldman increased its position 54% in January, according to regulatory filings. Overall, banks reported holding at least 68% of GSXs outstanding shares, according to a Bloomberg analysis of filings. Banks held at least 40% of IQIYI Inc, a Chinese video entertainment company, and 29% of ViacomCBS -- all of which Archegos had bet on big.Im sure there are a number of really unhappy investors who have bought those names over the last couple of weeks, and now regret it, Doug Cifu, chief executive officer of electronic-trading firm Virtu Financial Inc., said Monday in an interview on Bloomberg TV. He predicted regulators will examine whether there should be more transparency and disclosure by a family office.Without the need to market his fund to external investors, Hwangs strategies and performance remained secret from the outside world. Even as his fortune swelled, the 50-something kept a low profile. Despite once working for Robertsons Tiger Management, he wasnt well-known on Wall Street or in New York social circles.Hwang is a trustee of the Fuller Theology Seminary, and co-founder of the Grace and Mercy Foundation, whose mission is to serve the poor and oppressed. The foundation had assets approaching $500 million at the end of 2018, according to its latest filing.Its not all about the money, you know, he said in a rare interview with a Fuller Institute executive in 2018, in which he spoke about his calling as an investor and his Christian faith. Its about the long term, and God certainly has a long-term view.His extraordinary run of fortune turned early last week as ViacomCBS Inc. announced a secondary offering of its shares. Its stock price plunged 9% the next day.The value of other securities believed to be in Archegos portfolio based on the positions that were block traded followed.By Thursdays close, the value of the portfolio fell 27% -- more than enough to wipe out the equity of an investor who market participants estimate was six to eight times levered.Its also hurt some of the banks that served Hwang. Nomura and Credit Suisse warned of significant losses in the wake of the selloff and Mitsubishi UFJ Financial Group Inc. has flagged a potential $300 million loss.You have to wonder who else is out there with one of these invisible fortunes, said Novogratz. The psychology of all that leverage with no risk management, its almost nihilism.(Updates with latest bank to detail exposure in penultimate paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.2021 Bloomberg L.P.

Link:

EDAP TMS S.A. (EDAP) Stock Jumps 18.8%: Will It Continue to Soar? - Yahoo Finance

A new study tested transcranial magnetic stimulation (TMS) for treating people with a bipolar disorder diagnosis. The researchers found that actual TMS was no better than a sham (fake) treatment.

The study was led by Lakshmi N. Yatham at the University of British Columbia Hospital in Canada and published in JAMA Network Open.

The specific type of intervention used is intermittent theta-burst stimulation (iTBS), a type of TMS. The researchers targeted the left dorsolateral prefrontal cortex (LDPC) in the brain. The goal was to relieve depression symptoms in people diagnosed with bipolar disorder.

iTBS was used, and the LDPC was targeted because these are currently popular TMS methods in depression treatment. Yatham writes:

There was no evidence of antidepressant superiority for active iTBS over sham iTBS, and safety is uncertain because 1 hypomanic switch occurred with active iTBS and a second occurred during the open-label phase.

That is, people randomly assigned to the fake treatment did just as well as people who received actual iTBS. Additionally, two people undergoing actual iTBS became hypomaniccompared with none who were receiving the sham treatment.

The study was double-blinded, meaning that neither the participants nor the researchers knew who was receiving iTBS and who was receiving the sham treatment. The randomized, controlled trial lasted for four weeks, with an additional four-week open-label phase during which there was no sham control group.

The 37 participants were required to have a diagnosis of bipolar disorder I or II, be currently experiencing a major depressive episode, and be currently taking a mood stabilizer and/or an antipsychotic drug. They were also required to have had no clinical response to the drugthat is, for the participants in this study, mood stabilizers and antipsychotics did not work to improve their symptoms.

People who had previously had no response to TMS were excluded, as were people who were suicidal, experiencing psychosis or substance abuse, or undergoing psychotherapy.

The study was intended to include 50 people in each group (totaling 100). However, the study was canceled early because TMS was so inadequate. Response rates were very low: 3 of the 19 people in the sham treatment group improved, while 3 of the 18 people in the active treatment group improved.

After eight participants dropped out, 29 participants completed the four-week randomized trial. 21 people then agreed to enter the open-label phase. Five of them dropped out, leaving 16 people to complete the open-label trial. Four of the 16 remaining people achieved clinical remission during the open-label phasebut there was no control group to compare these results to, so they could also have been due to the placebo effect or regression to the mean.

Although the researchers write that blinding integrity was preserved, they note that about half of the people in the study correctly guessed whether they received the active treatment or not. Additionally, people were far more likely to improve if they believed they had received the active treatmentwhich is evidence of a strong placebo effect.

Surprisingly, TMS is approved by the FDA for the treatment of depression for people with any diagnosis, including bipolar disorder. The researchers note that this is based on extrapolating findings from studies on people with a depression diagnosis rather than any actual evidence on bipolar disorder.

Nonetheless, this isnt the first study to demonstrate the ineffectiveness of TMS. A 2016 sham-controlled study of a different type of TMS (sequential bilateral repetitive transcranial magnetic stimulation) similarly found that the active treatment was ineffective in those with a bipolar disorder diagnosis.

Even in the treatment of people with a depression diagnosis rather than bipolar disorder, the evidence for the effectiveness of TMS is unclear. Three large, multisite trials found that TMS was ineffective.

A review by the Clinical TMS Society frames these findings positively, but the results are clear:

****

McGirr, A., Vila-Rodriguez, F., Cole, J., Torres, I. J., Arumugham, S. S., Keramatian, K., . . . & Yatham, L. N. (2021). Efficacy of active vs. sham intermittent theta-burst transcranial magnetic stimulation for patients with bipolar depression: A randomized clinical trial. JAMA Netw Open, 4(3), e210963. doi:10.1001/jamanetworkopen.2021.0963 (Link)

Go here to read the rest:

Transcranial Magnetic Stimulation (TMS) Ineffective for People with Bipolar Disorder - James Moore

Despite its proven efficacy for unipolar depression, intermittent theta burst transcranial magnetic stimulation (iTBS) appears to be ineffective in alleviating symptoms of bipolar depression, new research suggests.

Overall, investigators found that only 16% of participants responded to iTBS during the double-blind period of the trial, and the proportion of patients who responded to iTBS was the same as the proportion who responded to sham treatment. Moreover, in the open-label period of the study, only 24% of patients met the criteria for response. The trial was terminated early for futility.

"If a treating clinician decides to offer TMS to a bipolar depressed patient, we suggest that clinicians refrain from offering iTBS," senior author Lakshmi Yatham, MBBS, MBA, professor and head, Department of Psychiatry, and director of the Institute of Mental Health, University of British Columbia, Vancouver, Canada, told Medscape Medical News.

"Instead, we would advocate using traditional forms of TMS, such as HFS [high-frequency stimulation] to the left dorsolateral prefrontal cortex or LFS [low-frequency stimulation] to the right dorsolateral prefrontal cortex," said Yatham, who is also the president of the World Federation of Societies of Biological Psychiatry and the editor-in-chief of The Canadian Journal of Psychiatry.

The study was published online March 12 in JAMA Network Open.

Repetitive TMS (rTMS), a noninvasive neurostimulation treatment, is a first-line intervention in pharmacotherapy-resistant unipolar major depressive disorder (MDD).

Newer TMS protocols that use theta burst stimulation have "garnered significant research attention and evidence for antidepressant efficacy," the authors write. iTMS, in particular, has been shown to produce "lasting neurophysiological changes" and "antidepressant efficacy in MDD." Despite the "growing evidence base" supporting the use of iTBS for MDD, there has been insufficient research in the use of this modality for patients with bipolar depression.

"A meta-analysis we had conducted with data on a small number of bipolar patients who had participated in previous TMS trials showed that TMS is likely beneficial," said Yatham.

"Given that theta burst stimulation requires much less time commitment for patients, and given that this form of stimulation has shown benefit in unipolar depression, we wanted to test if this treatment would work for bipolar depression, especially because there are very few safe and effective treatments for this patient population," she said.

The researchers randomly assigned 37 patients with bipolar depression to receive either active iTBS that targeted the left dorsolateral prefrontal cortex or sham iTBS (n = 18 and n = 19, respectively). The patients were between the ages of 20 and 68 years (mean age, 43.86; 62% women). The patients had experienced no clinical response to 1 first-line treatments for an acute major depressive episode (MDE).

Patients who were acutely suicidal, who were experiencing psychosis, who had recently been diagnosed with a substance use disorder, or who had a variety of other medical or psychiatric comorbidities were excluded from the trial.

Patients who did not exhibit 50% reduction in score on the Montgomery-sberg Depression Rating Scale (MADRS) at the conclusion of the double-blind phase of the study were offered an additional 4 weeks of open-label iTBS.

The group that received sham treatment and the active-treatment group presented with similar baseline levels of depression of moderate severity (MADRS scores, 32.57 [mean SD, 4.00] and 33.38 [mean SD, 4.46], respectively).

During the double-blind phrase, two participants who were receiving iTBS and four participants who were receiving sham iTBS dropped out of the study; one participant in the active-iTBS group discontinued treatment after 3 weeks because of COVID-19-related institutional closures; and one participant in the active-iTBS group experienced a mood switch after the first treatment session.

The researchers found "no evidence for clinical superiority" of active iTBS in comparison with sham iTBS. There was no significant difference between the two groups in change of mean score on the MADRS (P = .91).

In fact, the least squares mean difference for MADRS scores at week 4 was -1.36 (95% CI, -8.92 to 6.19; P = .91) in favor of sham iTBS.

There were no differences in improvement between the groups with respect to use of different mood stabilizers, and there were no differences in rates of clinical response at the conclusion of the double-blind phase of the study.

There were no differences between the two groups in self-reported depressive or anxiety symptoms following the intervention.

Of the 29 participants who completed the double-blind phase of the trial, 21 entered the open-label phase. Of these, 16 completed all 4 weeks of treatment.

After the double-blind phase, five patients in the open-label phase of the trial achieved clinical response, and four achieved clinical remission (23.8% and 19.0%, respectively). Of the five patients who experienced clinical response, three had been allocated to the sham-iTBS condition during the double-blind phase.

rTMS has been shown to be effective for unipolar depression but not for bipolar depression, because "these two conditions are likely biologically different," said Yatham.

"There are examples of other treatments that have worked in unipolar but not in bipolar depression for instance, commonly used antidepressants such as SSRIs [selective serotonin reuptake inhibitors] work very well for unipolar depression, but their efficacy in bipolar depression remains unproven," she said.

Commenting on the study for Medscape Medical News, Scott Aaronson, MD, director of clinical research, Shepherd Pratt, Towson, Maryland, expressed concern "that people might extrapolate data from this study to think that TMS doesnt work for bipolar depression."

Aaronson, an adjunct professor at the University of Maryland School of Medicine, Baltimore, Maryland, who was not involved with the study, said the investigators "have come to the right conclusion, which is the tendency for all of us to look at all TMS techniques as the same."

In an accompanying commentary, Joan Camprodon, MD, MPH, PhD, chief of the Division of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, said the study "emphasizes the need to deepen our characterization of circuit pathophysiology, the identification of anatomical treatment targets, and the focus on oscillatory physiological dynamics to understand both disease mechanisms and the distinct mechanisms of action (and clinical indications) of different TMS frequency interventions."

The study was supported by a philanthropic donation through the University of British Columbia.Yatham has received honoraria or research grants from Allergan, CANMAT, Lundbeck, Otsuka, DSP, Sanofi, Intracellular Therapies, AbbVie, Merck, and Sunovion. The other authors' disclosures are listed on the original article. Camprodon has served on the scientific advisory board of Hyka and Feelmore Labs and has received consultation honoraria from Neuronetics. His research is currently funded by the National Institutes of Health, the AE foundation, the Solinsky Foundation, and the Gerstner foundation. Aaronson is a consultant for I Neuronetics, a company that makes TMS devices.

JAMA Netw Open. Published online March 12, 2021. Full text, Commentary

For more Medscape Psychiatry news, join us on Facebook and Twitter.

View original post here:

New Efficacy Data on Theta Burst TMS for Bipolar Depression - Medscape

Sandhya Prashad, MD is medical director at Houston Ketamine Therapeutics and Houston Deep Transcranial Magnetic Stimulation (TMS) Therapy.

There is no question that the pandemic has shaped myriad aspects of life as we know it, including significantly impacting the mental health care industry. While the unprecedented events have resulted in mental health challenges, it has also delivered growth in the area as well.

In fact, the appetite for treatment has increased so much that providers are finding it challenging to accommodate the surge of requested appointments.1 This new found openness among patients to explore therapy has served as a means to deliver more care to those who have lived in silence for years due to either apprehension around going into an office or limited understanding around just how far treatment options have come.

Teletherapy has helped shepherd more patients through the door

Leveraging teletherapy has helped providers and patients troubleshoot the common concerns around social distancing and, ultimately, could be credited with getting many first-time patients in the virtual door. In fact, the use of teletherapy saw a 154% increase in March 2020 when compared to the same period in 2019.2 The ability to connect with patients in the comfort and privacy of their own homes allowed providers to build rapport over time and helped spark many overdue conversations around tailored options for treatment. While the convenience of teletherapy is likely to foster continued use long after the pandemic subsides, it is important for providers to remind patients that it is not a direct substitute for an in-person visit nor is it the only form of treatment available.

Taking the next step in treatment with the latest technology

Marrying the increased desire to speak with providers and the ability to ease into sessions via virtual visits, providers like myself have a unique opportunity to begin educating patients that mental health treatment is not a one-size-fits-all approach. Studies have shown that depression symptom prevalence is more than 3-fold higher3 during the COVID-19 pandemic, and because more than 40% of people with major depressive disorder (MDD)4 find they are treatment-resistant, there is a growing need to foster education among patients regarding other available options when there is an unresponsiveness to traditional methods.5 These options include deep transcranial magnetic stimulation (Deep TMS), a noninvasive treatment process that is FDA-cleared for treating depression and obsessive-compulsive disorder (OCD). While well-known within the mental health community, many patients are unaware of this successful treatment option which only takes 20-minutes per session.

In a study published by the Journal of Psychiatric Research, Deep TMS therapy combined with standard medication for MDD was found to be significantly more effective than standard pharmacotherapy alone, reducing the symptoms of close to two-thirds of participants battling depression.6 Deep TMS is a great example of how far we have come in treatment offerings, showing patients that there are treatments that do not require downtime, are noninvasive, and offer virtually no discomfort.

Moving forward in the new normal

While we as a society are working hard to leave the pandemic behind as a footnote in history, we as mental health professionals have been given a catalyst for a mental health movement. The pandemic has helped break down barriers such as the stigma around treatment, access to care in terms of proximity and available time, and even common misconceptions of what it means to receive treatment for depression. It is our responsibility as those committed to improving mental health to look for every opportunity we can to serve and educate, and the pandemic has certainly provided us with a platform.

Sandhya Prashad, MD is a board-certified psychiatrist specializing in interventional modalities for treatment-resistant disorders with a particular interest and expertise in ketamine therapy. She is the founder and medical director of Sandhya J. Prashad, MD, Houston Ketamine Therapeutics, and Houston TMS Therapeutics. Dr Prashad currently serves as president of The American Society of Ketamine Physicians, Psychotherapists and Practitioners.

References

1. Caron C. Nobody Has Openings: Mental Health Providers Struggle to Meet Demand. The New York Times. https://www.nytimes.com/2021/02/17/well/mind/therapy-appointments-shortages-pandemic.html. Published online February 17, 2021. Accessed February 17, 2021

2. Koonin LM, Hoots B, Tsang CA, et al. Trends in the use of telehealth during the emergence of the COVID-19 pandemic United States, JanuaryMarch 2020. MMWR Morb Mortal Wkly Rep. 2020;69:15951599. doi:10.15585/mmwr.mm6943a3

3. Ettman CK, Abdalla SM, Cohen GH, Sampson L, Vivier PM, Galea S. Prevalence of depression symptoms in US adults before and during the COVID-19 pandemic. JAMA Netw Open. 2020;3(9):e2019686. doi:10.1001/jamanetworkopen.2020.19686

4. Major Depressive Disorder and TMS Treatment. Brainsway. https://www.brainsway.com/knowledge-center/major-depressive-disorder-tms-treatment/. Accessed February 9, 2019

5. Jaffe DH, Rive B, Denee TR. The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional study. BMC Psychiatry. 19, 247 (2019). doi:10.1186/s12888-019-2222-4

6. Filipi I, imunovi Filipi I, Milovaca Z, et al. Efficacy of repetitive transcranial magnetic stimulation using a figure-8-coil or an H1-Coil in treatment of major depressive disorder; A randomized clinical trial. J. Psychiatr. Res. 2019;114:113-119. doi:10.1016/j.jpsychires.2019.04.020

Read this article:

The COVID-19 Pandemic: Helping Those Who Suffer in Silence - Psychiatry Advisor

DataIntelo has published a latest report on Global Transcranial Magnetic Stimulators (TMS) Market report. This report has been prepared by primary interviews and secondary research methodology. The market report provides detailed insights on the product pricing & trends, market drivers, and potential lucrative opportunities, during the forecast period, 2020-2027. Additionally, it covers market challenges and threats faced by companies.

Competitive Landscape

The market report provides information about the companys product, sales in terms of volume and revenue, technologies utilized, and innovations carried out in recent years. Additionally, it provides details on the challenges faced by them in the market.

The major players of the Transcranial Magnetic Stimulators (TMS) market are:

YiruideNeuroneticsMagstimBrainswayMagVentureeNeuraRemedNeurosoftDr. Langer MedicalNexstimYiruide

Note: Additional or specific companies can be profiled in the list at no extra cost.

Get free sample report @ https://dataintelo.com/request-sample/?reportId=164413

During the preparation of the report, the research team conducted several interviews with key designated executives and experts of the market. This, in turn, has helped them to understand the overall scope and complex matrix of the Transcranial Magnetic Stimulators (TMS) market. The market research report includes crucial data and figures about the report that aids the esteemed reader to make crucial business decisions. These data and figures are added in a concise manner in form of infographics and tables to save time.

Transcranial Magnetic Stimulators (TMS) Market Report Gives Out FREE COVID-19 Chapter

The COVID-19 pandemic had forced government state bodies across the globe to impose lockdown, which in turn, derailed the entire economy. Manufacturing facilities, schools, colleges, and offices witnessed a complete shutdown for few months in 2020. This resulted in the slowdown in the sales of products, which majorly impacted the growth rate of the market. Conversely, new market opportunities were explored and indeed created lucrative opportunities for the industry players.

The COVID-19 chapter covers the impact of pandemic on the market in a detailed manner. This includes product launches and strategies implemented by the industry players in the trying times. It discusses new market avenues, revenue drivers, untapped opportunities, and top-winning strategies in the market.

The research team has monitored the market closely in COVID-19 pandemic and conducted interviews with the market experts to understand the impact of coronavirus pandemic on the Transcranial Magnetic Stimulators (TMS) market. Moreover, the market provides information on the long-term challenges industry players is anticipated to face due to the pandemic.

Buy the complete report @ https://dataintelo.com/checkout/?reportId=164413

In-depth Insights on the Market Segments

The market segmentation are the vital fragments of the market. This report covers the types of the products available in the market, their applications and end-uses. Moreover, it includes the regional landscape of the market.

This part of the report covers the raw materials used for the products, supply & demand scenario, and potential applications of the products in the coming years. The market segmentation also provides in-depth insights on the regional market performance. This means that the regional landscape covers products sales in terms of volume and revenue from 2017 to 2020. Moreover, it provides insights on the expected performance of the product segment during the forecast period.

The global Transcranial Magnetic Stimulators (TMS) report gives in detailed insights on the regional landscape, which involves determining the potential of worth of investment in the particular region/country. Moreover, it gives out information about the market share of the industry players in the particular region.

Products

STMSPTMSRTMSnTMS

Applications

DepressionTinnitusAlzheimerParkinsons DiseasePsychiatric DisordersHeadacheStroke

Regions

North AmericaEuropeAsia PacificMiddle East & AfricaLatin America

Note: Country of your choice can be added at no extra cost. However, if one more than country needs to be added in the list, the research quote will vary accordingly.

The complete Transcranial Magnetic Stimulators (TMS) report can be tailored according to the clients requirements.

Below is the TOC of the report:

Executive Summary

Assumptions and Acronyms Used

Research Methodology

Transcranial Magnetic Stimulators (TMS) Market Overview

Global Transcranial Magnetic Stimulators (TMS) Market Analysis and Forecast by Type

Global Transcranial Magnetic Stimulators (TMS) Market Analysis and Forecast by Application

Global Transcranial Magnetic Stimulators (TMS) Market Analysis and Forecast by Sales Channel

Global Transcranial Magnetic Stimulators (TMS) Market Analysis and Forecast by Region

North America Transcranial Magnetic Stimulators (TMS) Market Analysis and Forecast

Latin America Transcranial Magnetic Stimulators (TMS) Market Analysis and Forecast

Europe Transcranial Magnetic Stimulators (TMS) Market Analysis and Forecast

Asia Pacific Transcranial Magnetic Stimulators (TMS) Market Analysis and Forecast

Asia Pacific Transcranial Magnetic Stimulators (TMS) Market Size and Volume Forecast by Application

Middle East & Africa Transcranial Magnetic Stimulators (TMS) Market Analysis and Forecast

Competition Landscape

If you have any doubts regarding the report @ https://dataintelo.com/enquiry-before-buying/?reportId=164413

About DataIntelo

DataIntelo has extensive experience in the creation of tailored market research reports in several industry verticals. We cover in-depth market analysis which includes producing creative business strategies for the new entrants and the emerging players of the market. We take care that our every report goes through intensive primary, secondary research, interviews, and consumer surveys. Our company provides market threat analysis, market opportunity analysis, and deep insights into the current and market scenario.

To provide the utmost quality of the report, we invest in analysts that hold stellar experience in the business domain and have excellent analytical and communication skills. Our dedicated team goes through quarterly training which helps them to acknowledge the latest industry practices and to serve the clients with the foremost consumer experience.

Contact Info:

Name: Alex Mathews

Address: 500 East E Street, Ontario,

CA 91764, United States.

Phone No: USA: +1 909 545 6473

Email:[emailprotected]

Website:https://dataintelo.com

Excerpt from:

Transcranial Magnetic Stimulators (TMS) Market 2021 Will Reflect Significant Growth in Future with Size, Share, Growth, and Key Companies Analysis-...

The market has been high on Edap Tms SA (EDAP) stock recently. EDAP gets a Bullish score from InvestorsObserver's Stock Sentiment Indicator.

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.

As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.

Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.

InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.

Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

Edap Tms SA (EDAP) stock is trading at $9.34 as of 12:34 PM on Tuesday, Mar 30, a loss of -$0.34, or -3.55% from the previous closing price of $9.68. The stock has traded between $9.02 and $9.75 so far today. Volume today is 352,472 compared to average volume of 291,615.

To see InvestorsObserver's Sentiment Score for Edap Tms SA click here.

Edap TMS SAis a holding company operating in two divisions namely, High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS). The HIFU division develops, manufactures and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets two HIFU devices: the Ablatherm, treatment of organ-confined prostate cancer; and the Focal One, for the focal therapy of localized prostate cancer destroying targeted cancer cells only. The UDS division develops, markets, manufactures and services medical devices for the invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The business of the presence of the firm are sen Asia, France, United States and other regions.

Click Here to get the full Stock Score Report on Edap Tms SA (EDAP) Stock.

Excerpt from:

Where Will Edap Tms SA (EDAP) Stock Go Next After It Is Higher By 19.44% in a Week? - InvestorsObserver

Global Talent Management Software (TMS) Market to witnessed good recovery in growth and projected coverup market sizing during the forecast period (2020-2027). The assessment provides a 360 view and insights outlining the key outcomes of the Talent Management Software (TMS) market, current scenario analysis that highlights slowdown aims to provide unique strategies and solutions following and benchmarking key players strategies. In addition, the study helps with competition insights of emerging players in understanding the companies more precisely to make better informed decisions. some of the key players that are part of coverage are Cornerstone Ondemand, IBM, Lumesse, Oracle, Peoplefluent, Skillsoft, Saba, SAP Successfactors, Talentsoft, Halogen.

COVID-19 can affect the global economy in 3 main ways: by directly affecting production and demand, by creating supply chain and market disturbance, and by its financial impact on firms and financial markets

Ask for sample:https://www.readmarketresearch.com/sample-request/129684-global-talent-management-software-tms-market

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type:

Professional Services, Training And Education, Support And Maintenance

On the basis of applications, the market has been segmented into:

BFSI, Healthcare, IT And Telecom, Retail, Manufacturing, Education, Government, Media And Entertainment

Top Companies covered in the report: Cornerstone Ondemand, IBM, Lumesse, Oracle, Peoplefluent, Skillsoft, Saba, SAP Successfactors, Talentsoft, Halogen

Read Full TOC of Talent Management Software (TMS) Research Study at @www.readmarketresearch.com/industry-report/129684/global-talent-management-software-tms-market

Research Methodology:

Years considered for the study are:Historical year 2016-2019Disreputable year 2020Estimate period** 2020 to 2027 [** unless otherwise stated]

Primary Research:

The primary sources involve the industry experts from the Global Talent Management Software (TMS) industry including the management organizations, processing organizations, analytics service providers of the industrys value chain. All primary sources were interviewed to gather and authenticate qualitative & quantitative information and determine the future prospects.In the extensive primary research process undertaken for this study, the primary sources industry experts such as CEOs, vice presidents, marketing director, technology & innovation directors, founders and related key executives from various key companies and organizations in the Global Talent Management Software (TMS) industry have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

Secondary Research:

In the Secondary research crucial information about the industries value chain, total pool of key players, and application areas. It also assisted in market segmentation according to industry trends to the bottom-most level, geographical markets and key developments from both market and technology-oriented perspectives.

Table of ContentsGlobal Talent Management Software (TMS) Market Research Report 2020-2027, by Manufacturers, Regions, Types and Applications

1 Talent Management Software (TMS) Market Overview1.1 Introduction1.2 Scope1.3 Assumptions1.4 Players Covered1.5 Market Analysis By Type1.5.1 Global Talent Management Software (TMS) Market Size Growth Rate By Type (2020-2027)1.5.2 1.6 Market By Application1.6.1 Global Talent Management Software (TMS) Market Share By Application (2020-2027)1.6.2 Application I1.6.3 Application Ii1.6.4 1.7 Study Objectives1.8 Years

2 Executive Summary

3 Talent Management Software (TMS) Market Analysis By Type (Historic 2016-2020)3.1 Global Talent Management Software (TMS) Market Size Analysis (USD Million) 2016-20203.1.1 Type I3.1.2 Type II3.2 Global Talent Management Software (TMS) Market Share Analysis By Type (%) 2016-2020

4 Talent Management Software (TMS) Market Analysis By Application (Historic 2016-2020)4.1 Global Talent Management Software (TMS) Market Size Analysis (USD Million) 2016-2019

5 Talent Management Software (TMS) Market Analysis By Regions (Historic 2016-2020)5.1 Global Talent Management Software (TMS) Market Size Analysis (USD Million) 2016-20205.1.1 Talent Management Software (TMS) Market Share By Regions (2016-2020)5.1.2 United States5.1.3 Europe5.1.4 China5.1.5 Japan5.1.6 India5.1.7 Rest Of The World

6 Key Companies Analysis/Company Profile

Continued..

Buy the Up-to-date Full Report @www.readmarketresearch.com/checkout?buynow=129684-global-talent-management-software-tms-market

Key Questions Answered by Talent Management Software (TMS) Market Report

1. What was the Talent Management Software (TMS) Market size in 2019 and 2020; what are the estimated growth trends and market forecast (2020-2027).2. What will be the CAGR of Talent Management Software (TMS) Market during the forecast period (2020-2027)?3. Which segments (product type/applications/end-user) were most attractive for investments in 2018? How these segments are expected to grow during the forecast period (2020-2027).4. Which manufacturer/vendor/players in the Data Management Platform Market was the market leader in 2020?5. Overview on the existing product portfolio, products in the pipeline, and strategic initiatives taken by key vendors in the market.

Enquire for Discount in Report @www.readmarketresearch.com/check-discount/129684-global-talent-management-software-tms-market

About UsWe at Read offers wide range of business services including but not limited to Market Research, Syndicate and Custom Research, Company Research, Business Consulting, Audit & Risk, Communications, Finance, Information Technology, Legal & Compliance, Human Resources and Sales.Contact:Read Market ResearchSatish K. (Global Sales Manager)B-51 CMPDI, Korba, ChhattisgarhPhone: +1 646 583 1932Email:https://www. readmarketresearch.comFollow Us on:LinkedIN

Read more:

Talent Management Software (TMS) Market explored in the latest research report by Read Market Research- Cornerstone Ondemand, IBM, Lumesse and Others...

"Responsiveness to customer needs is a core part of MagVenture DNA," says MagVenture SVP of Sales, Kerry Rome. "MagVenture is continuously striving to improve solutions to optimize the clinical practice of transcranial magnetic stimulation or TMS in short. In recent years, the clinical market for TMS has expanded at such a rapid pace that manufacturers are being challenged to keep pace with the technological requirements emerging with the exponential expansion in the demand for utilization. We've seen MagVenture drive an FDA clearance for the ultra-fast 'Theta Burst' TMS which has reduced treatment times for patients from 37 to just 3 minutes. Now, with the introduction of a remarkedly smooth solution to help TMS operators quickly and easily prepare patients for treatment, MagVenture is further improving the efficiency and experience of TMS for patients and operators alike," states Kerry Rome.

The latest improvement to the MagVenture TMS Therapy system, deemed the 'MagVenture Flow Arm', concerns the applicator 'coil'.The coil is essentially two very heavy spools of copper wire that produce and focus the magnetic fields for the non-invasive brain stimulation technique. The typically large and unwieldy coils, by necessity, have to be accurately positioned and held immobile over the brain target(s) during the TMS procedures. Over the past year, MagVenture product engineers and application experts, in close collaboration with MagVenture customers in the USA, Europe, Australia, and Asia, perfected a solution that vastly improves ease of use for MagVenture TMS operators to now, almost effortlessly, move and securely position TMS coils for non-invasive brain stimulation (TMS) procedures.

Kerry Rome goes on to add: "Throughout the R&D and testing phases for the Flow Arm project, the MagVenture organization here in the US has been waiting with much anticipation and, finally, we are super excited about the introduction of MagVenture's patent-pending 'Flow Arm' for TMS coil positioning. It's a game changer for TMS providers seeking optimal ease of use and efficiency in their clinical TMS services and, in context with the current COVID-19 pandemic, the improvements in the MagVenture reduced treatment/operator-patient interaction time is going to prove to be a big positive."

Transcranial Magnetic Stimulation is a technology that applies rapidly changing magnetic fields to stimulate specific areas in the brain. TMS has been available as a tool for non-invasive brain stimulation for more than three decades and is currently used extensively in clinical psychiatry, and for ongoing academic medical and translational neuroscience research. MagVenture TMS Therapy is FDA cleared as a treatment for major depressive disorder (MDD) and as an adjunct therapy treatment for obsessive-compulsive disorder (OCD). MagVenture TMS Therapy is an outpatient procedure with a well-tolerated safety profile with no systemic side effects. The most common side effects are headaches and nausea. MagVenture TMS Therapy has been clinically available in the USA since 2015 and is currently delivered at hospitals and psychiatric practices nationwide.

Contact details: Kerry Rome, Vice President Sales, MagVenture Inc., USA: 310 213 2697, email: [emailprotected]

MagVenture TMS Therapy FDA clearances: "Treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode and as an "adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD)".

MagVenture is a Danish medical device company specializing in non-invasive magnetic stimulation solutions for the clinical treatments and brain research. In 2018, MagVenture was the first TMS company to receive FDA clearance for Express TMS, reducing treatment time from the standard 37 minutes to just 3 minutes per session.

MagVenture A/S has over 25 years of experience within neuromodulation. From its headquarters in Denmark, MagVenture's products are manufactured and promoted worldwide through direct sales subsidiaries in the US, Brazil, Germany, the UK, and through an extensive global network of dedicated distributors in Europe, Asia, Middle East, and the Americas.

* Pat. EP 20214073.7 / US 63/125,594.

SOURCE MagVenture

Excerpt from:

MagVenture introduces new solution to improve the ease of use for non-invasive brain stimulation - PRNewswire

TORONTO--(BUSINESS WIRE)--Greenbrook TMS Inc. (TSX: GTMS) (Greenbrook or the Company) is pleased to announce that its common shares have been approved for listing and trading in U.S. dollar currency on the NASDAQ Stock Market LLC (NASDAQ). Trading on the NASDAQ will commence at the start of trading on March 16, 2021 under the symbol GBNH. Greenbrooks common shares will continue trading on the Toronto Stock Exchange in Canadian dollar currency under the symbol GTMS.

The listing of our common shares on the NASDAQ marks a significant milestone in the history of our Company, commented Bill Leonard, President and Chief Executive Officer of Greenbrook. We believe that the NASDAQ listing will provide significant benefits, including increased visibility of the Company amongst investors, increased access to capital and potential for greater liquidity.

About Greenbrook TMS Inc.

Operating through 126 Company-operated treatment centers, Greenbrook is a leading provider of Transcranial Magnetic Stimulation (TMS) therapy, an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Greenbrook has provided more than 510,000 TMS treatments to over 14,000 patients struggling with depression.

Cautionary Note Regarding Forward-Looking Information

Certain information in this press release, including with respect to the trading of Greenbrooks common shares on the NASDAQ, constitute forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as plans, targets, expects or does not expect, is expected, an opportunity exists, is positioned, estimates, intends, assumes, anticipates or does not anticipate or believes, or variations of such words and phrases or state that certain actions, events or results may, could, would, might, will or will be taken, occur or be achieved. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent managements expectations, estimates and projections regarding future events.

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this press release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the Risk Factors section of the Companys current annual information form available at http://www.sedar.com and http://www.sec.gov. These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Link:

Greenbrook to Commence Trading on NASDAQ - Business Wire

DALLAS, March 17, 2021 (GLOBE NEWSWIRE) -- Axele, LLC, a Transportation Management System (TMS) company, announces that Director of Strategy and Business Development, Ryan Camacho, has been named a 2021 Pro to Know. This prestigious award from Supply & Demand Chain Executive, the only publication covering the entire global supply chain, recognizes outstanding executives whose accomplishments leverage supply chains for competitive advantage.

Being named a Pro to Know is a testament to Ryans perfect execution of Axele TMSs vision, making the solution a one-stop-shop for small-to-midsized carriers that automates day-to-day operations and increases profits, said Ravi Ahuja, Founder & CEO, Axele. Our customers regularly compare the technology to that of an iPhone easy to use and delivering a tremendous amount of value. They feel like they have bought a $150,000 system for only dollars a day.

"While many companies have struggled to regain their footing as a result of COVID-19, this year's Pros to Know winners stepped up to the plate to deliver innovative solutions and programs in a time of crisis and need. These winners collaborated, optimized, developed, educated, and played a critical role in the survival and success of their company amid a global pandemic," says Marina Mayer, Editor-in-Chief of Supply & Demand Chain ExecutiveandFood Logistics. I am honored to recognize these individuals and teams and extend my utmost gratitude to everyone in the supply chain industry for their time, efforts, and innovations to keep our nation's supply chains afloat."

For the small-to-midsized truckload carrier, access to a comprehensive TMS has long been out of reach. Most legacy systems are either premise-based solutions requiring expensive hardware and an onsite IT support system or are priced unattainably. Axeles vision is to build a robust TMS with advanced integrations to load boards, ELDs, factoring companies, and back-end accounting systems and make it available through the cloud at an affordable price. No other vendor provides significant system advancements like optimization, artificial intelligence, automation, and more within their TMS at a cost attainable for small companies.

Ryan Camacho has worked for several high-profile logistic software companies, such as Oz Development, Descartes System Group, Kuebix, and Trimble. He has developed a tremendous amount of software and transportation industry expertise with many years in this space. He has held positions from the ground up to leadership positions, including customer support manager, software developer, implementation specialist, executive sales representative, senior sales engineer, and director of product management. At Axele, Ryan drives strategy and product evolution of the Axele Transportation Management System; the first SaaS-based TMS built specifically for the small-to-midsized full truckload carrier.

The 2021 Pros to Know award includes individuals and teams from software and service providers, consultancies and academia, trucking and transportation firms, professional development agencies, sourcing, and procurement divisions, and more, all who have helped supply chain clients and the supply chain community at large prepare to meet many of today'sand tomorrow'schallenges.

Go towww.sdcexec.com to view the complete list of all 2021 Pros to Know winners.

About Axele

Axele offers transportation management system (TMS) cloud software for truckload carriers leveraging decades of experience and insights into optimization and automation technology. Launched by Optym in 2020, Axele is the industry's first intelligent, connected solution, built specifically for small to mid-sized truckload carriers. Axele serves for-hire truckload operators and private fleets who haul general freight, dry van, flatbed, and refrigerated loads. The Axele TMS integrates with load boards, ELDs, market rates, maps, and accounting systems, to enable an owner-operator or carrier to find better loads, increase profits, and grow their business. For more information about Axele, go to http://www.axele.com.

AboutSupply & Demand Chain Executive

Supply & Demand Chain Executiveis the only supply chainpublication covering the entire global supply chain, focusing on trucking, warehousing, packaging, procurement, risk management, professional development, and more. Go towww.SDCExec.com.

Media Contact for Axele:Becky BoydMediaFirst PR(770) 642-2080 x 214Cell (404) 421-8497Becky@MediaFirst.Net

Visit link:

Axele Executive Named to SDCE 2021 Pros to Know - GlobeNewswire